La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Small Pharma Bilan de santé

Santé financière contrôle des critères 4/6

Small Pharma possède un total de capitaux propres de CA$8.0M et une dette totale de CA$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont CA$12.9M et de CA$4.9M.

Informations clés

Ratio d'endettement

CA$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CA$7.68m
Fonds propres	CA$8.05m
Total du passif	CA$4.88m
Total des actifs	CA$12.92m

Mises à jour récentes de la santé financière

Recent updates

We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Aug 26

Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Feb 13

Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

Oct 30

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de DMT ( CA$12.4M ) dépassent ses passifs à court terme ( CA$4.7M ).

Passif à long terme: Les actifs à court terme de DMT ( CA$12.4M ) dépassent ses passifs à long terme ( CA$154.3K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: DMT est sans dette.

Réduire la dette: DMT n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: DMT dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: DMT dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 47.3 % chaque année

Small Pharma Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Small Pharma Inc. Common Stock to Be Deleted from OTC Equity

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

Recent updates

Small Pharma Inc. Common Stock to Be Deleted from OTC Equity

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

Insider recently sold CA$284k worth of stock

Small Pharma Inc. Reports Positive Top-line Data from SPL026 (DMT-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Small Pharma Inc., Annual General Meeting, Oct 12, 2023

We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Insider recently sold CA$101k worth of stock

Small Pharma Inc. Announces Management Changes

Small Pharma Inc. Confirms the First Subject Has Been Dosed in A Phase I Study Evaluating SPL028

Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Small Pharma Inc. Reports Positive Top-Line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Small Pharma Confirms First Patient Dose in its Phase I Study Exploring Intramuscular Administration of SPL026

Small Pharma Inc. Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Price target decreased to CA$1.42

High number of new and inexperienced directors

Small Pharma Inc. Receives Approval for First-In-Human Phase I Clinical Trial with SPL028

Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients with Major Depressive Disorder

Key Executive recently bought CA$61k worth of stock

Small Pharma Inc. Receives Approval for DMT-Assisted Psychotherapy and Ssri Drug Interaction Study

Small Pharma Inc. Announces CEO Changes, Effective from July 20, 2022

Small Pharma Inc., Annual General Meeting, Jul 19, 2022

Small Pharma Inc. Announces Appoints Alastair Riddell as Chief Operating Officer

Small Pharma Inc. Announces Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

Small Pharma Inc. Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy

Small Pharma Inc. Expands Phase I/IIa Clinical Trial With Additional Study Site

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines